Apellis Pharmaceuticals

Where you target the complement cascade matters. At Apellis, we go to the center – C3, the central protein addressing all three activation pathways.     By targeting C3, we can control complement overactivation while preserving essential immune function – helping address some of the most challenging diseases that patients face. Learn more: https://bit.ly/4jvgRbz  

Team Apellis kicked off the new year with a focus on collaboration and connection. Being together strengthens our culture, drives innovation, and fuels the work we do for patients.    Join our fearless team: https://bit.ly/4ntHr51     #WeAreApellis 

Great news for patients – the European Commission has granted our partner Sobi approval for our C3G and primary IC-MPGN treatment! Building on our U.S. approval, this marks the first-ever treatment for patients 12 and older in the EU. Read more: http://bit.ly/3NgyhN3

Apellis is pleased to be in Waikoloa this week for the Hawaiian Eye & Retina 2026 Meeting! Stop by booth #204 and attend our presentations to learn more about our commitment to transforming care for patients with #GeographicAtrophy (GA) secondary to AMD.   #WeAreApellis #HawaiianEyeandRetina 

We’re pleased to share an update on the meaningful progress achieved across our business in 2025 and the priorities positioning Apellis for continued momentum in 2026.   Our CEO Cedric Francois will discuss this today at the J.P. Morgan Healthcare Conference in San Francisco at 11:15am PT / 2:15pm ET. Read more: https://bit.ly/4jBUJMl   https://bit.ly/4pq9JOS   #JPM2026

We’re heading out to San Francisco for the J.P. Morgan Healthcare Conference. Our CEO Cedric Francois will present on Monday, January 12, at 11:15 a.m. PT/2:15 p.m. ET. Learn more: https://bit.ly/3LxI9kN   See you there!   #WeAreApellis #JPM2026

Thank you to #TeamApellis for making meaningful progress for patients in 2025—including our third regulatory approval in just four years and launching our treatment for C3G and primary IC-MPGN—and making a positive impact in our communities!   Wishing our team, partners, patients, and care partners a restful holiday season! As we head into the new year, we’re energized to keep pushing forward with courageous science and compassion for patients.

We’re embracing the holiday spirit and our “We Care” value by giving back to our local community!   #TeamApellis donated to Toys for Tots, an organization we’re proud to support to spread cheer among children in Massachusetts.   #WeAreApellis

Celebrating our values in action! At this year’s Annual Values Awards, we recognized #TeamApellis colleagues whose leadership and impact inspire us every day. Join us in congratulating our winners.👏   #WeAreApellis

"Although the disease is rare, you’re not alone. Other patients are out there." Lindsey, who is living with C3G, knows firsthand how isolating it can feel after receiving a rare kidney disease diagnosis. Hear Lindsey’s advice for those diagnosed with a rare kidney disease below and access patient resources at: https://bit.ly/4r5DJS5   #WeAreApellis